UCB has become the latest focus of inquiries by Chinese officials in a growing clampdown on drug pricing and marketing practices in the country.
The Belgian pharmaceutical company confirmed it had been inspected this week by the State Administration for Industry and Commerce, one of several antitrust regulators.
The action came in the week Chinese police accused GlaxoSmithKline of being the “godfather” of a network of companies involved in bribery totalling nearly $500m over the past six years.
您已閱讀33%（497字），剩餘67%（1010字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。